Trial Profile
A Multicenter, Randomized, Double-blind, Placebo Controlled Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly Compared to Placebo in Osteoporotic Children Treated With Glucocorticoids.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Corticosteroid-induced osteoporosis; Osteoporosis
- Focus Registrational; Therapeutic Use
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 06 Jul 2021 Primary endpoint (Mean Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) Z-score at Month 12) has been met as per results published in the Journal of Clinical Endocrinology and Metabolism
- 06 Jul 2021 Results published in the Journal of Clinical Endocrinology and Metabolism
- 10 Sep 2018 This trial has been discontinued in UK-MHRA (End date : 2018-03-05)